Personalized DC Vaccine for Postoperative Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-100
SponsorSichuan University
About this trial
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Eligibility criteria
Qualifiers
Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
Anticipated life time > 3month
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Adequate organ functions
Disqualifiers
Any evidence of tumor metastasis or co-existing malignant disease
Tumor emergency
Abnormal coagulation condition
Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
Trial design
Treatments tested in this trial
- DC vaccine subcutaneous administration
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov